ClinicalTrials.gg
CompletedNCT01087151Updated Nov 2, 2016

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of ABT-263 and rituximab in Chronic Lymphocytic Leukemia, sponsored by Genentech, Inc.. Completed at 103 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
25th of 189
118 · median 39
Started
2010
with 7 others
Phase 2
119 of 197
1 open now
Registered
136th of 197
by date

Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 25th largest by enrollment of the 189 interventional ones that give a count, is one of 8 that started in 2010, is one of 119 in phase 2, and was the 136th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This Phase II, randomized, open-label, international, multicenter trial is designed to evaluate the safety and efficacy of rituximab monotherapy when given according to a dose intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when combined with dose-intense rituximab in previously untreated patients with B-cell CLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Rituxan
  • Apoptosis
  • BCl-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated, CD20-positive B-cell CLL
  • performance status of 0 or 1
  • > 6 months
  • Willingness and capability to be accessible for follow-up until study termination or death
  • For patients of (both males and females), use of a reliable means of

Exclusion criteria

Exclusion Criteria:

  • Prolymphocytic leukemia
  • Richter's transformation to an aggressive B-cell (e.g., DLBCL)
  • Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of progression at baseline
  • Patients with a history of other malignancies within 2 years prior to study entry except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, low-grade, localized prostate cancer treated surgically with curative intent or one that carries a good prognosis, in situ ductal carcinoma of the breast treated with lumpectomy alone with curative intent
  • Prior treatment with rituximab, ABT-263 or other pro-apoptotic agents
  • Current or recent (within the 28 days prior to initiation of study treatment) participation in another experimental drug study
  • Major surgical procedure (excluding lymph node ) or significant traumatic injury within 28 days prior to treatment onset or anticipation of the need for major surgery during the course of the study
  • Active infection requiring parenteral antibiotics or antiviral or antifungal agents at the onset of study treatment
  • Receipt of primary or booster vaccination with live-virus vaccines for up to 6 months prior to initiation of study treatment
  • Patients receiving therapeutic anticoagulation with heparin or warfarin or patients receiving any drugs or herbal supplements that are known to inhibit function (including low-dose aspirin) within 7 days of the first dose of ABT-263. Note: Patients receiving low-dose anticoagulation for the purpose of maintaining central venous catheter patency are eligible.
  • Patients who have an inherited or acquired bleeding diathesis, including (but not limited to) hemophilia or immune or thrombotic thrombocytopenic purpura, or who have had an underlying condition that predisposes to abnormal bleeding (e.g., peptic ulcer disease) within 1 year prior to the first dose of ABT-263
  • Patients with a history of refractoriness to platelet transfusions
  • cardiovascular disease
  • Known (HIV) infection, seropositivity for surface antigen (HBsAg) or virus (HCV) antibody or RNA
  • Pregnancy or breastfeeding
  • Concurrent (or within 7 days prior to the first dose of study treatment) systemic therapy except some low-dose corticosteroid therapies
  • History of other disease, metabolic dysfunction, physical or laboratory finding(s) giving reasonable suspicion of a disease or condition that contraindicates use of an drug, might affect interpretation of the results of the study or render the patient at high risk from treatment complications
  • History of anaphylaxis, allergic reaction, or to sulfites (sodium metabisulphite is included in study drug formulation)
  • Any to alcohol ingestion (study drug formulation includes approximately 15% ethanol)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Active comparator
    A

    Drug: rituximab

  • Experimental
    B

    Drug: ABT-263 · Drug: rituximab

  • Experimental
    C

    Drug: ABT-263 · Drug: rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time frame: From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from First Patient In [FPI])

Secondary outcomes

  1. Overall response rate (ORR)

    Time frame: Approximately 40 months from FPI

  2. Duration of response

    Time frame: Approximately 40 months from FPI

  3. Complete response (CR) rate

    Time frame: Approximately 40 months from FPI

  4. Progression-free survival as assessed by a blinded, independent review

    Time frame: From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from FPI)

  5. ORR as assessed by a blinded, independent review

    Time frame: Approximately 40 months from FPI

  6. Duration of response as assessed by a blinded, independent review

    Time frame: Approximately 40 months from FPI

  7. CR rate as assessed by a blinded, independent review

    Time frame: Approximately 40 months from FPI

  8. Overall survival (OS)

    Time frame: From randomization until death due to any cause (approximately 4 years after Last Patient In)

07

Study locations

103 sites
  • Alhambra, California 91801, United States
  • Antioch, California 94531, United States
  • Berkeley, California 94704, United States
  • Burbank, California 91505, United States
  • Duarte, California 91010, United States
  • Dublin, California 94568, United States
  • La Jolla, California 92093, United States
  • Los Angeles, California 90024, United States
  • Los Angeles, California 90073, United States
  • Los Angeles, California 90095-1772, United States
  • Los Angeles, California 90095, United States
  • Northridge, California 91325, United States
  • Pleasant Hill, California 94523, United States
  • San Leandro, California 94578-2626, United States
  • San Luis Obispo, California 93454, United States
  • Santa Monica, California 90404, United States
  • Fort Collins, Colorado 80528, United States
  • Norwalk, Connecticut 06856, United States
  • Bay Pines, Florida 33744, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60612, United States
  • Decatur, Illinois 62526, United States
  • Harvey, Illinois 60426, United States
  • Tinley Park, Illinois 60477, United States
  • Shreverport, Louisiana 71103, United States
  • Baltimore, Maryland 21215, United States
  • Bethesda, Maryland 20817, United States
  • Bethesda, Maryland 20874, United States
  • Randallstown, Maryland 21133, United States
  • Lansing, Michigan 48909, United States
  • Lansing, Michigan 48912, United States
  • Omaha, Nebraska 68114, United States
  • Henderson, Nevada 89052, United States
  • Las Vegas, Nevada 89148, United States
  • Las Vegas, Nevada 89169, United States
  • Reno, Nevada 89502, United States
  • Cherry Hill, New Jersey 08003, United States
  • Farmington, New Mexico 87401, United States
  • Oneida, New York 13421, United States
  • Oswego, New York 13126, United States
  • Syracuse, New York 13210, United States
  • Middletown, Ohio 45042, United States
  • Philadelphia, Pennsylvania 19111, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Corpus Christi, Texas 78405, United States
  • Lubbock, Texas 79410, United States
  • Lubbock, Texas 79415, United States
  • Everett, Washington 98201, United States
  • Randwick, New South Wales 2031, Australia
  • Greenslopes, Queensland 4120, Australia
  • Adelaide, South Australia 5000, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Coburg, VIC, Victoria 3058, Australia
  • Fitzroy, Victoria 3065, Australia
  • Frankston, Victoria 3199, Australia
  • Parkville, Victoria 3052, Australia
  • Fremantle, Western Australia 6160, Australia
  • Cachoeiro de Itapemirim, ES 29308-014, Brazil
  • Belo Horizonte, MG 30150-270, Brazil
  • Belo Horizonte, MG 30150-281, Brazil
  • Rio de Janeiro, RJ 20211-030, Brazil
  • Caxias do Sul, RS 95070-560, Brazil
  • Porto Alegre, RS 90020-090, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Porto Alegre, RS 90110-270, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • São Paulo, SP 01427-001, Brazil
  • Brno, 625 00, Czech Republic
  • Hradec Kralove, 500 05, Czech Republic
  • Prague 2, 128 08, Czech Republic
  • Lille, 59037, France
  • Pierre Benite, 69495, France
  • Afula, 18101, Israel
  • Petah Tikva, 4937211, Israel
  • Ramat Gan, 5262100, Israel
  • Rehovot, 76100, Israel
  • Modena, Emilia-Romagna 41100, Italy
  • Genova, Liguria 16128, Italy
  • Cremona, Lombardia 26100, Italy
  • Milano, Lombardia 20133, Italy
  • Milano, Lombardia 20162, Italy
  • Rozzano, Lombardia 20089, Italy
  • Torino, Piemonte 10128, Italy
  • Chorzow, 41-500, Poland
  • Gdansk, 80-952, Poland
  • Warszawa, 00-909, Poland
  • San Juan, 00927, Puerto Rico
  • Kazan, 420029, Russian Federation
  • Moscow, 115478, Russian Federation
  • Petrozavodsk, 185019, Russian Federation
  • Ryazan, 390039, Russian Federation
  • St. Petersburg, 191024, Russian Federation
  • Cherkassy, 18009, Ukraine
  • Dnipropetrovsk, 49102, Ukraine
  • Donetsk, 83045, Ukraine
  • Ivano-Frankivsk, 76018, Ukraine
  • Khmelnitskyy, 29000, Ukraine
  • Kyiv, 03150, Ukraine
  • Lviv, 79044, Ukraine
  • Poltava, 36024, Ukraine

Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 16, 2010
Start
Aug 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results delay requested
Aug 20, 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01087151
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 16, 2010
Start date
Aug 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Nov 2, 2016

Study contacts

William Ho, M.D., Ph.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Navitoclax · Rituximab

Start the discussion